 |
|
|
|
Executives
James A. Bannon, Executive Chairman
Most recently, Dr Bannon has been the Group President for several late stage Covance businesses including Clinical, Central Diagnostics, IVRS and Periapproval Services. These businesses delivered clinical trial services globally to more than 35 countries. He expanded the service reach to Central and Eastern Europe, South and Central America and Asia. He implemented an organizational realignment that created improved standardization and consistent service delivery within the same disciplines across multiple businesses. The result has been improved quality of performance, improved client satisfaction, an increase in repeat business and expanded margins.
Prior to Covance, over a 25-year clinical research career, Dr. James A. Bannon has held various positions of increasing responsibility in operations and executive management at various businesses. He built his career by using his deep understanding of the drug approval process and his technical training to lead the operations group of the Corning Pharmaceuticals Periapproval business. In this position, he had overall global responsibility for the delivery of all aspects of projects including project management, monitoring, data management and safety reporting. He consistently demonstrated his intense focus on client satisfaction leading to the delivery of high quality service and significant repeat business. In addition, he was responsible for improving the overall performance of the data management and safety group by the incorporation of leading edge technologies including optical character recognition, relational database management and web-based adverse event management and reporting. These enhancements led to consistently improved service delivery, performance and profitability.
In 1995, he became the General Manager of the Corning Pharmaceutical Services Periapproval business. Under his executive leadership the sales, revenue and operating margin doubled twice over an 8-year period. During this time, the business was recognized with the Houghton Quality Award. This award recognized the Corning business unit that successfully implemented and utilized the Total Quality System to drive both client and employee satisfaction. As a result of these quality systems, the Periapproval business unit achieved consistently high customer satisfaction and employee satisfaction ratings resulting in a significant increase in repeat business and low employee turnover.
Over his career, he has had oversight for research projects involving hundreds of products across a broad range of therapeutic areas and medical specialties. He is an experienced executive with a history of successful performance who understands both the technical and business aspects of the clinical research industry.
Edward J. Brennan Jr., M.D.,
Fellow, American College of Surgeons -
President and CEO
Dr. Brennan is President and CEO of IndiPharm. He possesses detailed knowledge of the clinical trial needs of Western Pharma companies based upon years of performing clinical trials. He also has experience as a principal investigator, thus providing additional credibility with both clients and Indian physicians.
Prior to joining IndiPharm in early 2007, Dr. Brennan was Director of Clinical Pharmacology and Discovery Medicine at GlaxoSmithKline plc (GSK). At GSK, Dr. Brennan was responsible for coordinating all clinical activities for external partners within GSK’s Center of Excellence in External Drug Discovery (CEEDD). Prior to joining the CEEDD, Dr. Brennan was Director of Clinical Pharmacology within the MMPD CEEDD at GSK where he was responsible for the development of multiple compounds from pre-Candidate Selection through Proof of Concept. Before joining GSK, Dr. Brennan held clinical development positions of increasing responsibility at both Johnson & Johnson and Wyeth.
Dr. Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic areas, including oncology, infectious diseases, immunology and critical care. He has led teams that have filed more than 10 Investigational New Drug Applications, as well as multiple New Drug and Supplemental New Drug Applications.
Dr. Brennan received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science. He went on to study medicine at The Royal College of Surgeons in Ireland before receiving his Medical Degree from Temple University School of Medicine. He completed his residency in General Surgery at the Lankenau Hospital and Medical Research Center, and, after completing his fellowship in Advanced Minimally Invasive Surgery at the Minimally Invasive Surgical Training Institute (Baltimore, MD), he returned to join the staff at Lankenau, where he held a teaching appointment from Thomas Jefferson College of Medicine. While on the staff at Lankenau, Dr. Brennan also served as Surgical Residency Director.
Dilip R. Limaye - Vice-Chairman
Mr. Limaye is Founder and Vice-Chairman of IndiPharm and is responsible for business development, financial management, and overall corporate oversight and guidance. Mr. Limaye is an internationally-recognized entrepreneur and consultant and has been a senior advisor to international organizations such as the World Bank, the International Finance Corporation, the United Nations, and the United States Agency for International Development. He has conducted a number of projects for these organizations.
As an entrepreneur, Mr. Limaye has established a variety of international organizations in a wide range of fields including energy efficiency, renewable energy, global climate change, information technology (IT), and business process outsourcing (BPO). Mr. Limaye is the founder and major shareholder in INTESCO-Asia limited, an energy services company, and Synergic India Private Limited, a solar integrator company. In addition, as principal of Yuvis, Inc., he helped establish ValueCAD Inc., an outsourcing company for architectural drawings, Medscribe, a medical transcription services company, and Epiance India Pvt. Ltd. (formerly Guru Computers), a software company. Most of these ventures have involved the establishment of a U.S.-based organization for client interface and client services combined with an Indian operation to execute projects and programs efficiently and effectively thereby providing clients global quality services with a local U.S. interface at a substantially lower cost than would be available in developed countries. After successfully implementing this business model in the fields of renewable energy, energy services, IT and BPO, Mr. Limaye created IndiPharm for effectively outsourcing clinical trials to India for Pharma companies, thereby obtaining the timing and cost savings available in India.
Mr. Limaye earned his Bachelor of Technology degree from one of the premier technology institutions in the world, The Indian Institute of Technology (IIT), Bombay, where he graduated #1 in his class and received the prestigious President of India Gold Medal. He earned his M.S. from Cornell University and has completed his Ph.D. candidacy examination in international business from the Wharton School, University of Pennsylvania. Mr. Limaye has published six books and has presented over 50 technical papers at national and international conferences. |
|
|
|
|
|
